Is Shilajit Safe for Women Over 50? What the Research Actually Shows

Quick answer: Yes, by the evidence we have. Across every human clinical study on shilajit ever published, zero serious adverse events have been reported. The largest trial in postmenopausal women ran 48 weeks with safety labs drawn throughout and found no woman quit due to side effects and no abnormal bloodwork at any point. Below is the full picture, including the heavy metals question most women ask first, what independent purity testing looks for, and the two situations where honest gaps in the research exist.

The heavy metals question most women ask first

Shilajit is a mineral resin that forms over thousands of years as plant and microbial matter compresses in mountain rock. The honest question is whether all those minerals include the wrong ones.

Here is what the research shows.

A 2024 systematic review in the Journal of Trace Elements in Medicine and Biology analyzed heavy metal content in shilajit from multiple sources. The finding that surprises most people comes down to basic chemistry. The humic and fulvic acids in shilajit are not neutral carriers that simply deliver whatever happens to be in the rock. They actively bind and detoxify heavy metals, including lead, cadmium, arsenic, and about twelve others. The same substance that concentrates beneficial minerals is also doing a form of internal chelation on the unwanted ones.

Commercial testing confirms this plays out in practice. A 2021 ICP-MS study published in Nutrients tested multiple commercial shilajit products and found all of them met FDA limits for arsenic, mercury, lead, and cadmium.

Geography matters too. A 2025 study in PMC analyzed thallium content by region and found that samples from Iran's Saravan source ran notably higher (0.226 µg/g) than samples from India (0.007 µg/g). Altai-sourced shilajit was not the concern.

None of this means every shilajit product is automatically safe. It means that purified, third-party tested shilajit from a reputable source is supported by the chemistry and the data. Unpurified or unverified material is not.

What the human clinical data shows

The clearest window into safety is the study that ran the longest in the population that matters most.

The 2022 Pingali trial enrolled 60 postmenopausal women, aged 45 to 60, all with existing bone loss. They took purified shilajit daily for 48 weeks, close to a full year. Safety labs were drawn at the start, at 24 weeks, and at 48 weeks. At the end, not one woman dropped out because of a side effect. Every blood safety lab stayed inside the normal range throughout.

Vitamin D levels did not change in any group. That detail matters because it rules out the bone results being driven by hidden vitamin D supplementation.

The broader literature adds to that picture. A 2014 review by Stohs and colleagues in Phytotherapy Research covered the accumulated human and animal shilajit research available at the time and concluded it was generally well tolerated across all studies examined.

The toxicology research

Researchers have also tested shilajit in high-dose animal protocols specifically designed to find where toxicity begins.

A 2012 study in the Asian Pacific Journal of Tropical Biomedicine dosed rats at up to 5,000 mg per kilogram of body weight for 91 consecutive days and found no organ toxicity, no unusual iron changes, and normal tissue histology throughout. That ceiling is far above anything a person would ever take.

A 2020 study in PMC ran a 90-day repeated-dose protocol on a combined fulvic and humic preparation and found no genotoxicity, no organ toxicity, and no general toxicity at any level tested.

Animal toxicology does not automatically translate to people, but the pattern across these studies is consistent. Purified shilajit and its active compounds sit well outside the danger range at human therapeutic doses.

The cancer question and what the cell research shows

Women who have had breast cancer, or who carry relevant risk factors, often want to know specifically whether shilajit interacts with estrogen-sensitive conditions.

This is the right question. Here is the honest answer.

The fulvic acid in shilajit is not a hormone. It supports the body's own estrogen signaling rather than adding estrogen. That distinction matters for the cancer concern.

Beyond the hormone question, researchers have tested fulvic acid directly against breast cancer cells. A 2016 study in PLOS ONE found that fulvic acid triggered macrophage-mediated death in cancer cells including MCF-7, the ER-positive breast cancer cell line, while leaving healthy cells intact. Follow-up mouse research and later in vitro work found similar patterns.

These are cell-level and animal studies, not clinical trials in women with breast cancer. They do not prove shilajit prevents or treats cancer. What they show is that the fulvic acid in shilajit was not found to stimulate cancer cell growth, and in these lab conditions it moved the other direction. The estrogen concern does not have evidence behind it for this specific compound.

What third-party testing actually means

Quality control is the missing piece in most safety discussions about supplements.

Third-party testing means an independent laboratory, not the manufacturer, runs the analysis. For a mineral resin like shilajit, the lab is measuring arsenic, mercury, lead, and cadmium against FDA limits and California Prop 65 standards, testing for mycotoxins (mold-related compounds that can form in organic matter), and confirming the fulvic acid percentage, since the active component drives the dose.

A certificate of analysis should be publicly available for any lot. It should show the lab name, the testing date, and specific numeric results next to the reference limits. A document that just says "passed" without numbers is not a certificate of analysis.

Optimum shilajit comes from the Altai mountains, cold-pressed and purified. Every batch is tested by an independent third-party laboratory and is heavy metal free and Prop 65 compliant. We are a small, family-owned company out of Florida, and a real person answers when someone reaches out.

Two situations where the research has honest gaps

The overall safety picture is well-supported. Two specific situations sit outside the data.

Women who take blood thinners should know that direct drug-interaction studies between shilajit and anticoagulant medications are essentially absent from the published research. There are no reported serious incidents in the literature. But there is also no controlled data on that interaction. Women on blood thinners are outside the population where the safety evidence has been gathered, and thin evidence is different from evidence of harm.

Women who are pregnant or breastfeeding are similarly outside the studied population. Shilajit has a long history in Ayurvedic practice, but the modern pregnancy safety literature in humans is absent.

These are not reasons to panic. They are honest acknowledgments that two groups fall outside the data we have.

What this means for you

The safety picture for purified, third-party tested shilajit in women over 50 is well-supported. The longest human trial in postmenopausal women returned clean labs and zero safety events across 48 weeks. The toxicology research shows a wide margin between the therapeutic dose and where problems begin. The heavy metals concern is addressed by the chemistry of fulvic acid and by independent testing.

The honest caveat is that the human trial literature is still limited in volume. More long-term trials in postmenopausal women would strengthen this further. What exists is consistent, specific to the right population, and pointing in one direction.

You can find Optimum Shilajit here: https://www.liveoptimum.co/products/optimum-shilajit

Frequently asked questions

Is shilajit safe for postmenopausal women?

Based on the available human clinical data, yes. The 2022 Pingali trial ran 48 weeks in 60 postmenopausal women and found no adverse events, no abnormal bloodwork, and no dropouts due to side effects. Across all human shilajit studies combined, zero serious adverse events have ever been reported. More long-term trials in postmenopausal women would strengthen the picture, but what exists is consistently clean.

Does shilajit contain heavy metals?

The raw resin can concentrate minerals from the rock, which is why purity testing matters. The humic and fulvic acids in shilajit actively bind many heavy metals, reducing them in the purified material. A 2021 ICP-MS study found commercial samples all met FDA limits for arsenic, mercury, lead, and cadmium. Look for a certificate of analysis from an independent lab showing actual values.

Is shilajit safe for women concerned about breast cancer?

The fulvic acid in shilajit supports estrogen signaling without adding estrogen. Cell research found it triggered cancer cell death in ER-positive MCF-7 cells while leaving healthy cells intact. These are cell studies, not human trials, but they point away from the concern rather than adding to it.

Can women on blood thinners take shilajit?

Direct human drug-interaction studies between shilajit and anticoagulant medications are essentially absent from published research. No serious incidents have been reported, but there is no controlled data on this interaction. Women on blood thinners are outside the population where the safety data has been gathered.

How do I know if a shilajit product is safe?

Look for a certificate of analysis from an independent third-party laboratory showing heavy metal values, mycotoxin results, and a fulvic acid percentage with the lab name and specific numbers visible. California Prop 65 compliance is a useful benchmark. Altai-sourced shilajit has a better thallium profile than some other regional sources.

References

1. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
2. Stohs SJ, et al. A review of the efficacy and safety of Shilajit (Mumie, Moomiyo). Phytotherapy Research. 2014. https://pubmed.ncbi.nlm.nih.gov/23733436/
3. Velmurugan C, et al. Safety and toxicological study of black shilajit after 91-day repeated oral dosing in rats. Asian Pacific Journal of Tropical Biomedicine. 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3609271/
4. Systematic review of heavy metal content in shilajit. Humic substances actively bind and detoxify approximately 12 metals. Journal of Trace Elements in Medicine and Biology. 2024. https://pubmed.ncbi.nlm.nih.gov/38393486/
5. ICP-MS quantification of commercial shilajit. All samples met FDA limits for arsenic, mercury, lead, and cadmium. Nutrients. 2021. https://pubmed.ncbi.nlm.nih.gov/34800280/
6. Thallium content in shilajit by source geography. Altai region not elevated; Iran/Saravan highest. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11743217/
7. Fulvic and humic acid 90-day toxicology study. No genotoxicity, no organ toxicity at any dose tested. PMC. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505752/
8. Fulvic acid and MCF-7 breast cancer cells. Macrophage-mediated cancer cell death; healthy cells spared. PLOS ONE. 2016. https://pubmed.ncbi.nlm.nih.gov/27177083/